Compare
ADMA Biologics, Inc. vs Twist Bioscience Corp vs Immunocore Holdings plc vs Repligen Corp
| Latest fiscal year | ADMA Biologics, Inc. ADMA | Twist Bioscience Corp TWST | Immunocore Holdings plc IMCR | Repligen Corp RGEN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-09-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $510.17M | $459.43M | $400.02M | $738.26M |
| Revenue growth (YoY) | +19.6% | +22.0% | +29.0% | +16.4% |
| Gross margin | 57.4% | 52.4% (computed) | n/a | 52.3% (computed) |
| Operating margin | 37.5% | -30.4% | -11.3% | 7.5% |
| Net margin | 28.8% | -28.3% | -8.9% | 6.6% |
| Net income | $146.93M | -$130.20M | -$35.51M | $48.89M |
| EPS (Diluted) | $0.60 | -$2.08 | -$0.71 | $0.86 |
| Operating cash flow | $50.40M | -$41.43M | -$10.71M | $117.42M |
| Free cash flow | $27.82M | -$89.01M | -$15.05M | $93.90M |
| Cash & equivalents | $87.63M | $533.99M | $467.71M | $566.02M |
| Total assets | $624.24M | $1.12B | $1.07B | $2.95B |
| Total liabilities | $146.92M | $233.79M | $686.24M | $843.57M |
| Shareholders' equity | $477.32M | $888.02M | $381.03M | $2.11B |
| Return on year-end equity | 30.8% | -14.7% | -9.3% | 2.3% |
| Shares outstanding | 237.87M | 67.81M | 50.69M | 56.33M |
Revenue, most recent five fiscal years
| Fiscal year | ADMA Biologics, Inc. | Twist Bioscience Corp | Immunocore Holdings plc | Repligen Corp |
|---|---|---|---|---|
| Latest | $510.17M Ended 2025-12-31 | $459.43M Ended 2026-09-30 | $400.02M Ended 2025-12-31 | $738.26M Ended 2025-12-31 |
| 1 year earlier | $426.45M Ended 2024-12-31 | $376.57M Ended 2025-09-30 | $310.20M Ended 2024-12-31 | $634.44M Ended 2024-12-31 |
| 2 years earlier | $258.21M Ended 2023-12-31 | $312.97M Ended 2024-09-30 | $249.43M Ended 2023-12-31 | $632.36M Ended 2023-12-31 |
| 3 years earlier | $154.08M Ended 2022-12-31 | $245.11M Ended 2023-09-30 | $174.36M Ended 2022-12-31 | $801.54M Ended 2022-12-31 |
| 4 years earlier | $80.94M Ended 2021-12-31 | $203.56M Ended 2022-09-30 | $36.48M Ended 2021-12-31 | $670.53M Ended 2021-12-31 |